Kephera Diagnostics is focused on developing innovative immunoassays for diagnosing a variety of infectious diseases, particularly those that are emerging or neglected. The company employs both lab-based and point-of-care technologies to create diagnostic tests that can significantly impact global health. Their current offerings include CLIA-certified laboratory tests for diseases such as Chagas disease, neurocysticercosis, liver fluke infection, and Lyme disease. Kephera's collaboration with prominent institutions like the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) underscores their commitment to advancing diagnostic capabilities for infectious diseases that affect millions worldwide.

A key aspect of Kephera's technology is their MiCRIA™ Open POC platform, which aims to revolutionize point-of-care testing. This platform allows for rapid, accurate testing using a microfluidic system that can be operated with standard laboratory equipment, making it accessible even in resource-limited settings. The tests are designed to be quick and simple, with results available in as little as two minutes, and they demonstrate sensitivity that rivals traditional lab-based methods like ELISA. By focusing on both lab-based assays and point-of-care solutions, Kephera Diagnostics is positioned to enhance the diagnosis and treatment of infectious diseases on a global scale.

United States

Kephera Diagnostics is a startup that aims to address the public health challenges of global infectious diseases with point of care assay technology.

Kephera Diagnostics

Company Details